Indaptus Therapeutics enters employment agreement with CFO Nir Sassi; base salary $345,000

Indaptus Therapeutics, Inc.

Annual base salary of $345,000 with annual review; eligible for target bonus up to 40% of base salary.
Prior consulting agreement terminated; separately agreed to pay $195,728 termination payment to Mr. Sassi.
Severance of 12 months base salary if terminated without cause or resigns for good reason.
Change-in-control severance: 12 months base plus target bonus, plus accelerated equity vesting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nir Sassi

Chief Financial Officer

INDP · Indaptus Therapeutics, Inc.

Effective: 2022-02-01
Filed: February 1, 2022, 6:59 PM ET

On February 1, 2022, Intec Pharma Ltd. (“Intec”), a wholly owned subsidiary of Indaptus Therapeutics, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Nir Sassi, the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nir Sassi was appointed as Chief Financial Officer at Indaptus Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On February 1, 2022, Intec Pharma Ltd. (“Intec”), a wholly owned subsidiary of Indaptus Therapeutics, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Nir Sassi, the Company’s Chief Financial Officer.

View on SEC.gov

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-002893

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.